Summary of the period 1 January to 31 March 2025

• Net turnover TSEK 200,998 (79,609)
• Cash flow from operating activities TSEK 28,296 (34,093)
• Result after financial items TSEK 119,352 (38,948)
• Result after tax TSEK 94,425 (35,667)
• Earnings per share TSEK 3.19 (1.35)

The entire quarterly report is available at: https://intellego-technologies.com/sv/rapporter/

A Message from the CEO
Starting the year with record revenue and profit, and we are not slowing down.

Intellego saw significant growth in Q1 with increases in revenue, profit and also receivables conversion into cash.
This is a testament to the innovative products that Intellego provide to the market and our close collaborations
with our customers e.g. Henkel and Likang. It also shows that Intellegos work with shortening payment times
is starting to have results, which we expect to continue to improve during the year. In addition, we do see that
our sales continue to accelerate in all business areas which is driven by our improving sales work, that Intellego
becomes a more recognized brand and regulations (in the UV disinfection industry). Due to our increasing
growth, Intellego hereby raises its 2025 financial goals to over 600 million (265) SEK in revenue and over
250 million (102) SEK in EBIT. If the company achieves these numbers, it will mean an increase in revenue of
approximately 126% and 145% increase in EBIT on a yearly basis.

During Q1 the company continued its investment in future growth. An example is market investments which
Intellego does with its partners e.g. Henkel and Likang and during Q1 approximately 10 MSEK was invested in
these collaborations, from the company operating cashflow. The basic reason for these investments is that the
company sees that these investments can significantly alter the financial curve of the group. The company has
previously said that its 3–5-year financial goal is to reach above 2 billion SEK in revenue. However, the group
now see that with the right investment, the group can reach over 10 billion in sales in the next 5 years. These
investments will mainly be in assets which will generate additional revenue, profit and cashflow further down the
road. As an example, one of these is the investment in capital equipment where the group recently received an
order for 100 UV disinfection devices. Investment in this type of equipment will enable for Intellego to sell more
UV dosimeters over a longer period of time. For example, a hospital can buy or lease a piece of equipment for a
relatively low up front cost but at the same time they commit to be buying dosimeter for a multi year period. The
company estimates that for every 1 SEK that it invest, it will get 5 SEK back over a 3 year period.

During the quarter we also continued to credit secure more receivables and we had approximately 77 million
SEK in available credit which hadn’t been used at the end of the quarter. If the company wishes, these credit
assured receivables can be used as collateral for loans or factoring. This puts the company in a comfortable
liquidity position. Together with the improved operational cashflow which is expected this year, the company
has more than enough to finance its operations ahead.

Two of our major collaborations with Henkel and Likang are developing better than expected. Both projects
generate revenue on a reoccurring basis and the volumes are increasing. At the time of this report, Likang has
started their expansion outside of China into the rest of the Asia region. With Henkel we are still discussing a
global distribution agreement, but that distribution agreement is secondary to our mutual focus on selling the
products in the market and the global launch which is the most important thing. Both Intellego and Henkel are
aiming to have the agreement signed shortly.

In addition to existing sales, Intellego is also involved in several development projects which we will inform
about as soon as there is concrete and relevant information to share. One of these projects is the collaboration
we have with HAI Solutions which is making good progress. HAI Solutions product has been registered and
launched in New Zeeland. At the same time the FDA has expressed that the material which HAI has filed is
acceptable, but that HAI also needs to file additional documentation due to their de novo application. This will
push back the expected acceptance date from this summer to the end of 2025.

Intellego’s improving results comes from the continuous work to improve every aspect of our business.
Furthermore, the disinfection business in particular is expected to benefit from new market standards and new
regulations where UV disinfection devices are facing more stringent demands for quality control. Based on this
and the progress that the company has made over past months, the management and board are now in process
of reviewing our 3-5 year goal which will be updated later this year.

Claes Lindahl
CEO of Intellego Technologies